blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3322719

EP3322719 - IL22 IMMUNOCONJUGATES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.10.2020
Database last updated on 12.11.2024
FormerThe patent has been granted
Status updated on  15.11.2019
FormerGrant of patent is intended
Status updated on  11.07.2019
FormerExamination is in progress
Status updated on  23.11.2018
FormerRequest for examination was made
Status updated on  20.04.2018
FormerThe international publication has been made
Status updated on  20.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Philogen S.p.A.
Piazza La Lizza, 7
53100 Siena / IT
[2018/21]
Inventor(s)01 / BOOTZ, Franziska Sophie
Birmensdorferstrasse 397
8055 Zürich / CH
02 / NERI, Dario
Zihlstrasse 35
8107 Buchs / CH
 [2018/21]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2019/51]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2018/21]Keirstead, Tanis Evelyne, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date16739166.315.07.2016
[2018/21]
WO2016EP66979
Priority number, dateGB2015001248616.07.2015         Original published format: GB 201512486
GB2015001764906.10.2015         Original published format: GB 201517649
GB2015002147004.12.2015         Original published format: GB 201521470
[2018/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017009469
Date:19.01.2017
Language:EN
[2017/03]
Type: A1 Application with search report 
No.:EP3322719
Date:23.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 19.01.2017 takes the place of the publication of the European patent application.
[2018/21]
Type: B1 Patent specification 
No.:EP3322719
Date:18.12.2019
Language:EN
[2019/51]
Search report(s)International search report - published on:EP19.01.2017
ClassificationIPC:C07K14/54, A61K38/20
[2018/21]
CPC:
C07K14/54 (EP,KR,US); A61K38/20 (EP,US); A61K47/6813 (EP,KR,US);
A61K47/6849 (EP,KR,US); A61K47/6851 (EP,KR,US); A61P1/04 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P37/02 (EP);
A61P9/10 (EP); C07K16/18 (EP,KR,US); C07K16/30 (KR,US);
C07K19/00 (US); A61K2039/505 (US); A61K38/00 (EP,KR,US);
C07K2317/56 (US); C07K2317/565 (US); C07K2317/622 (KR,US);
C07K2317/626 (KR,US); C07K2319/33 (EP,KR,US); C07K2319/70 (KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/21]
Extension statesBA14.02.2018
ME14.02.2018
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:IL22-IMMUNKONJUGATE[2018/21]
English:IL22 IMMUNOCONJUGATES[2018/21]
French:IMMUNOCONJUGUÉS D'IL22[2018/21]
Entry into regional phase14.02.2018National basic fee paid 
14.02.2018Designation fee(s) paid 
14.02.2018Examination fee paid 
Examination procedure14.02.2018Examination requested  [2018/21]
14.02.2018Date on which the examining division has become responsible
25.09.2018Amendment by applicant (claims and/or description)
22.11.2018Despatch of a communication from the examining division (Time limit: M04)
01.03.2019Reply to a communication from the examining division
12.07.2019Communication of intention to grant the patent
04.11.2019Fee for grant paid
04.11.2019Fee for publishing/printing paid
04.11.2019Receipt of the translation of the claim(s)
Opposition(s)21.09.2020No opposition filed within time limit [2020/48]
Fees paidRenewal fee
10.07.2018Renewal fee patent year 03
10.07.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.07.2016
AL18.12.2019
AT18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MK18.12.2019
MT18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE15.07.2020
LU15.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
[2022/32]
Former [2022/27]HU15.07.2016
AL18.12.2019
AT18.12.2019
CY18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
MT18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
TR18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE15.07.2020
LU15.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/37]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
IE15.07.2020
LU15.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/24]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
LU15.07.2020
BE31.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/20]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
LU15.07.2020
CH31.07.2020
LI31.07.2020
Former [2021/14]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
MC18.12.2019
NL18.12.2019
PL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/51]AL18.12.2019
AT18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SI18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/47]AL18.12.2019
CZ18.12.2019
DK18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/40]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
IS18.04.2020
PT13.05.2020
Former [2020/37]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
SK18.12.2019
SM18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
PT13.05.2020
Former [2020/36]AL18.12.2019
CZ18.12.2019
EE18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
PT13.05.2020
Former [2020/35]AL18.12.2019
CZ18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RO18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/32]AL18.12.2019
FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
NL18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/25]FI18.12.2019
HR18.12.2019
LT18.12.2019
LV18.12.2019
RS18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/23]FI18.12.2019
LT18.12.2019
LV18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
GR19.03.2020
Former [2020/22]FI18.12.2019
LT18.12.2019
SE18.12.2019
BG18.03.2020
NO18.03.2020
Former [2020/21]NO18.03.2020
Cited inInternational search[Y]WO2014145016  (GENENTECH INC [US], et al) [Y] 1-37 * claims 1, 40,47,82, 96,120 *;
 [Y]WO2014173570  (PHILOGEN SPA [IT]) [Y] 1-37 * claims 1, 5, 6, 8, 22, 30 *;
 [Y]  - KEN SUGIMOTO ET AL, "IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis", JOURNAL OF CLINICAL INVESTIGATION, US, (20080201), doi:10.1172/JCI33194, ISSN 0021-9738, XP055307663 [Y] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1172/JCI33194
 [Y]  - FRANZISKA BOOTZ ET AL, "Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease", INFLAMMATORY BOWEL DISEASES, US, (20150519), vol. 21, no. 8, doi:10.1097/MIB.0000000000000440, ISSN 1078-0998, pages 1908 - 1917, XP009191937 [Y] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1097/MIB.0000000000000440
 [Y]  - TERESA HEMMERLE ET AL, "The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer", INTERNATIONAL JOURNAL OF CANCER, (20130702), vol. 134, no. 2, doi:10.1002/ijc.28359, ISSN 0020-7136, pages 467 - 477, XP055121200 [Y] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1002/ijc.28359
 [Y]  - C. HESS ET AL, "Tumor-targeting properties of novel immunocytokines based on murine IL1 and IL6", PROTEIN ENGINEERING, DESIGN AND SELECTION, GB, (20140502), vol. 27, no. 6, doi:10.1093/protein/gzu013, ISSN 1741-0126, pages 207 - 213, XP055307661 [Y] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1093/protein/gzu013
 [Y]  - HEMMERLE TERESA ET AL, "Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IE, (20140815), vol. 76, no. 2, doi:10.1016/J.JDERMSCI.2014.07.012, ISSN 0923-1811, pages 96 - 103, XP029074445 [Y] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jdermsci.2014.07.012
 [Y]  - HESS CHRISTIAN ET AL, "The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, vol. 64, no. 5, doi:10.1007/S00262-015-1666-8, ISSN 0340-7004, (20150227), pages 635 - 644, (20150227), XP035485748 [Y] 1-37 * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-015-1666-8
 [T]  - FRANZISKA BOOTZ ET AL, "Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis", INFLAMMATORY BOWEL DISEASES, US, (20160802), vol. 22, no. 9, doi:10.1097/MIB.0000000000000851, ISSN 1078-0998, pages 2098 - 2105, XP055307423

DOI:   http://dx.doi.org/10.1097/MIB.0000000000000851
 [T]  - Franziska Bootz, "ANTIBODY-BASED PHARMACODELIVERY OF IMMUNOMODULATORS FOR THE TREATMENT OF ULCERATIVE COLITIS", (20160101), URL: http://e-collection.library.ethz.ch/eserv/eth:49100/eth-49100-01.pdf, (20161004), XP055307428
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.